BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 17847132)

  • 1. CE in anticancer metallodrug research--an update.
    Hartinger CG; Keppler BK
    Electrophoresis; 2007 Oct; 28(19):3436-46. PubMed ID: 17847132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins.
    Polec-Pawlak K; Abramski JK; Semenova O; Hartinger CG; Timerbaev AR; Keppler BK; Jarosz M
    Electrophoresis; 2006 Mar; 27(5-6):1128-35. PubMed ID: 16440400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP.
    Groessl M; Hartinger CG; Dyson PJ; Keppler BK
    J Inorg Biochem; 2008; 102(5-6):1060-5. PubMed ID: 18222004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: a novel approach for the analysis of anticancer metallodrugs in human serum and plasma.
    Groessl M; Hartinger CG; Polec-Pawlak K; Jarosz M; Keppler BK
    Electrophoresis; 2008 May; 29(10):2224-32. PubMed ID: 18512673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative binding of antitumor indazolium [trans-tetrachlorobis(1H-indazole)ruthenate(III)] to serum transport proteins assayed by capillary zone electrophoresis.
    Timerbaev AR; Rudnev AV; Semenova O; Hartinger CG; Keppler BK
    Anal Biochem; 2005 Jun; 341(2):326-33. PubMed ID: 15907879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of capillary electrophoresis-inductively coupled plasma mass spectrometry to comparative studying of the reactivity of antitumor ruthenium(III) complexes differing in the nature of counter-ion toward human serum proteins.
    Połeć-Pawlak K; Abramski JK; Ferenc J; Foteeva LS; Timerbaev AR; Keppler BK; Jarosz M
    J Chromatogr A; 2008 May; 1192(2):323-6. PubMed ID: 18433763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capillary electrophoresis-mass spectrometry for the analysis of intact proteins.
    Haselberg R; de Jong GJ; Somsen GW
    J Chromatogr A; 2007 Aug; 1159(1-2):81-109. PubMed ID: 17560583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probing the stability of serum protein-ruthenium(III) drug adducts in the presence of extracellular reductants using CE.
    Timerbaev AR; Foteeva LS; Rudnev AV; Abramski JK; Połeć-Pawlak K; Hartinger CG; Jarosz M; Keppler BK
    Electrophoresis; 2007 Jul; 28(13):2235-40. PubMed ID: 17557359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Separation and identification of platinum adducts with DNA nucleotides by capillary zone electrophoresis and capillary zone electrophoresis coupled to mass spectrometry.
    Warnke U; Gysler J; Hofte B; Tjaden UR; van der Greef J; Kloft C; Schunack W; Jaehde U
    Electrophoresis; 2001 Jan; 22(1):97-103. PubMed ID: 11197185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of binding constants and stoichiometries for platinum anticancer drugs and serum transport proteins by capillary electrophoresis using the Hummel-Dreyer method.
    Rudnev AV; Aleksenko SS; Semenova O; Hartinger CG; Timerbaev AR; Keppler BK
    J Sep Sci; 2005 Feb; 28(2):121-7. PubMed ID: 15754818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research.
    Brouwers EE; Tibben M; Rosing H; Schellens JH; Beijnen JH
    Mass Spectrom Rev; 2008; 27(2):67-100. PubMed ID: 18231971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.
    Brabec V; Nováková O
    Drug Resist Updat; 2006 Jun; 9(3):111-22. PubMed ID: 16790363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances of CE-ICP-MS in speciation analysis related to metalloproteomics of anticancer drugs.
    Timerbaev AR; Pawlak K; Aleksenko SS; Foteeva LS; Matczuk M; Jarosz M
    Talanta; 2012 Dec; 102():164-70. PubMed ID: 23182589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum metallodrug-protein binding studies by capillary electrophoresis-inductively coupled plasma-mass spectrometry: characterization of interactions between Pt(II) complexes and human serum albumin.
    Timerbaev AR; Aleksenko SS; Polec-Pawlak K; Ruzik R; Semenova O; Hartinger CG; Oszwaldowski S; Galanski M; Jarosz M; Keppler BK
    Electrophoresis; 2004 Jul; 25(13):1988-1995. PubMed ID: 15237398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capillary electrophoresis in anti-cancer metallodrug research: advances and future challenges.
    Hartinger CG; Timerbaev AR; Keppler BK
    Electrophoresis; 2003 Jun; 24(12-13):2023-2037. PubMed ID: 12858372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of platinum adducts with DNA nucleotides and nucleosides by capillary electrophoresis coupled to ESI-MS: indications of guanosine 5'-monophosphate O6-N7 chelation.
    Warnke U; Rappel C; Meier H; Kloft C; Galanski M; Hartinger CG; Keppler BK; Jaehde U
    Chembiochem; 2004 Nov; 5(11):1543-9. PubMed ID: 15515088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: new insights from X-ray diffraction and mass spectrometry studies.
    Casini A; Guerri A; Gabbiani C; Messori L
    J Inorg Biochem; 2008; 102(5-6):995-1006. PubMed ID: 18289690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A versatile approach for assaying in vitro metallodrug metabolism using CE hyphenated with ICP-MS.
    Abramski JK; Foteeva LS; Pawlak K; Timerbaev AR; Jarosz M
    Analyst; 2009 Oct; 134(10):1999-2002. PubMed ID: 19768206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ESI-MS characterisation of protein adducts of anticancer ruthenium(II)-arene PTA (RAPTA) complexes.
    Casini A; Mastrobuoni G; Ang WH; Gabbiani C; Pieraccini G; Moneti G; Dyson PJ; Messori L
    ChemMedChem; 2007 May; 2(5):631-5. PubMed ID: 17366652
    [No Abstract]   [Full Text] [Related]  

  • 20. Elucidation of the interactions of an anticancer ruthenium complex in clinical trials with biomolecules utilizing capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry. Short communication.
    Groessl M; Hartinger CG; Połeć-Pawlak K; Jarosz M; Dyson PJ; Keppler BK
    Chem Biodivers; 2008 Aug; 5(8):1609-1614. PubMed ID: 18729095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.